- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
- Drug
- Lead sponsor
- Amneal Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–76
of 76
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost SR, Standard of Care
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 66
- States / cities
- Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more
- Conditions
- Ocular Hypertension
- Interventions
- bimatoprost/timolol fixed combination
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Ogden, Utah
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5%, Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL
- Drug · Device
- Lead sponsor
- SpyGlass Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Glendale, Arizona